← Back to Clinical Trials
Recruiting NCT07161505

NCT07161505 Personalized Theta-burst Stimulation for Long-lasting Changes in Approach/Avoidance Behavior

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07161505
Status Recruiting
Phase
Sponsor Northwestern University
Condition Approach/Avoidance Behavior
Study Type INTERVENTIONAL
Enrollment 26 participants
Start Date 2025-07-31
Primary Completion 2026-08-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
TBS-EEGTBS-EEG / Spatial ControlTBS / Temporal Control

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 26 participants in total. It began in 2025-07-31 with a primary completion date of 2026-08-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study will assess the long-lasting effects of personalized theta burst stimulation (TBS), a repetitive form of transcranial magnetic stimulation (TMS), over the left prefrontal cortex on the approach/avoidance behavior. TBS will be personalized based on the prefrontal theta rhythm captured with electroencephalography (EEG). The main questions it aims to answer are: 1. does a single session of personalized TBS synchronized with the individual theta rhythm over the left prefrontal cortex results in the outlasting changes in the individual behavior? 2. Does TBS results in the brain rhythms' changes as measured using resting-state EEG?

Eligibility Criteria

Inclusion Criteria: 1. Participants must be legal adults between the ages of 18 to 65; 2. Able and willing to complete study procedures and tasks. Exclusion Criteria: 1. History or evidence of chronic neurological or mental disorder; 2. Chronic condition that requires pharmacological treatment over the course of study participation; 3. Pregnancy or breastfeeding; 4. History or evidence of alcohol or drug addiction; 5. Contraindications for transcranial magnetic stimulation (history of seizures, metallic or electric implant in the head/neck area); 6. Contraindications for magnetic resonance imaging at 3 Tesla (non-compatible implants, metallic foreign bodies, insulin pump, pacemaker).

Contact & Investigator

Central Contact

Ivan Alekseichuk, PhD

✉ neuromodlab@northwestern.edu

📞 312-503-3196

Principal Investigator

Ivan Alekseichuk, PhD

PRINCIPAL INVESTIGATOR

Northwestern University

Frequently Asked Questions

Who can join the NCT07161505 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Approach/Avoidance Behavior. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07161505 currently recruiting?

Yes, NCT07161505 is actively recruiting participants. Contact the research team at neuromodlab@northwestern.edu for enrollment information.

Where is the NCT07161505 trial being conducted?

This trial is being conducted at Chicago, United States.

Who is sponsoring the NCT07161505 clinical trial?

NCT07161505 is sponsored by Northwestern University. The principal investigator is Ivan Alekseichuk, PhD at Northwestern University. The trial plans to enroll 26 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology